GRIFFITH UNIVERSITY
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 1971-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.griffith.edu.au
Clinical Trials
188
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (178 trials with phase data)• Click on a phase to view related trials
Duration of Protection of Nirsevimab Against Hospitalisation for Respiratory Syncytial Virus Infection
- Conditions
- Respiratory Syncytial Viral (RSV) Infections
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Griffith University
- Target Recruit Count
- 4350
- Registration Number
- NCT06993753
- Locations
- 🇦🇺
Griffith University, Gold Coast, Queensland, Australia
Effect of Flexible Catheter Materials on Catheter Angle and Blood Vessel Irritation
- Conditions
- HealthyIntravenous CatheterizationOedemaThrombosis
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Griffith University
- Target Recruit Count
- 26
- Registration Number
- NCT06927141
- Locations
- 🇦🇺
Griffith University, Southport, Queensland, Australia
Different Efficacy of IFA Supplementation Among Obese and Non-obese Women
- Conditions
- Obesity and OverweightAnemia, Iron-Deficiency
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Griffith University
- Target Recruit Count
- 165
- Registration Number
- NCT06622551
- Locations
- 🇮🇩
Nutrition Laboratory, Faculty of Public Health Universitas Airlangga, Surabaya, East Java, Indonesia
News
FDA Grants Fast Track Designation to Sanofi's mRNA Chlamydia Vaccine Candidate
The US FDA has granted fast track designation to Sanofi's mRNA vaccine candidate for chlamydia prevention, recognizing its potential to address a serious unmet public health need.
First Clinical Trial of Olfactory Nerve 'Bridges' for Spinal Cord Injury Treatment Begins
A Phase I clinical trial has commenced to evaluate the safety and efficacy of transplanting olfactory ensheathing cell nerve bridges for chronic spinal cord injury.